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Background: Stage III non-small cell lung cancer (NSCLC) still has a poor prognosis. Prior studies with
individualized, accelerated, isotoxic dose escalation (INDAR) with 3D-CRT showed promising results,
especially in patients not treated with concurrent chemo-radiotherapy. We investigated if INDAR deliv-
ered with IMRT would improve the overall survival (OS) of stage III NSCLC patients treated with concur-
rent chemotherapy and radiotherapy.
Patients and methods: Patients eligible for concurrent chemo-radiotherapy were entered in this prospec-
tive study. Radiotherapy was given to a dose of 45 Gy/30 fractions BID (1.5 Gy/fraction), followed by QD
fractions of 2 Gy until a total dose determined by the normal tissue constraints. The primary endpoint
was OS, secondary endpoints were loco-regional relapses and toxicity.
Results: From May 4, 2009 until April 26, 2012, 185 patients were included. The mean tumor dose was
66.0 ± 12.8 Gy (36–73 Gy), delivered in a mean of 39.7 fractions in an overall treatment time of 38.2 days.
The mean lung dose (MLD) was 17.3 Gy. The median OS was 19.8 months (95% CI 17.3–22.3) with a 5-
year OS of 24.3%. Loco-regional failures as first site of recurrence occurred in 59/185 patients (31.8%).
Isolated nodal failures (INF) were observed in 3/185 patients (1.6%). Dyspnea grade 3 was seen in 3.2%
of patients and transient dysphagia grade 3 in 22%.
Conclusions: INDAR with IMRT concurrently with chemotherapy did not lead to a sign of an improved OS
in unselected stage III NSCLC patients.
 2019 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 135 (2019) 141–146Non-small cell lung cancer (NSCLC) stage III is diagnosed in
approximately 30% of lung cancer patients [1]. For the majority
of these patients, concurrent chemo-radiotherapy is the treatment
of choice [1]. Because the prognosis remains poor and the first site
of recurrence is local in about one third of patients, several
research groups have investigated radiation dose intensification
as a way to improve local tumor control and eventually the overall
survival (OS). In concurrent chemo-radiotherapy, dose escalation
by adding once-daily 2 Gy fractions did not improve the OS [2].
The results of randomized trials investigation dose re-
distribution within the tumor are awaited [3–5].
As another way to intensify and escalate the radiotherapy
dose without increasing toxicity, we and others have reportedon accelerated, individualized isotoxic dose escalation [6–12].
In non-concurrent radiotherapy schedules, acceleration of the
radiotherapy led to improved survival [13] and individualized
isotoxic dose prescription will push the dose to the upper limit
for each patient [11]. In non-concurrent chemotherapy and
radiotherapy or radiotherapy alone, this strategy appeared to
be promising, while the early results in concurrent chemo-
radiotherapy seemed to be similar to standard fractionation
radiotherapy [6,13]. However, these studies were done with
3-dimensional conformal radiotherapy (3D-CRT) techniques,
whereas with intensity modulated radiotherapy (IMRT) it is
expected that the dose may be increased further [14]. Moreover,
long-term results are lacking.
We therefore report here on the OS and toxicity results with a
minimum follow-up of 5 years of a prospective study of acceler-
ated, individualized isotoxic radiotherapy dose escalation with
concurrent chemotherapy in stage III NSCLC.
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Patients
From May 4, 2009 until April 26, 2012, patients eligible for con-
current chemo-radiation were entered in this prospective study
conducted at Maastro clinic, where the radiotherapy was delivered.
Systemic therapy was administered in the referring hospitals.
Included were patients with stage III (7th TNM edition), histologi-
cal or cytological confirmed NSCLC, no prior thoracic radiation and
a work-up according to national guidelines, including a staging
whole body FDG-PET-CT scan and a MRI or contrast-enhanced CT
scan of the brain. A WHO Performance Status (WHO PS) of 0 to 2
was required. All patients had to have a moderate to good lung
function (FEV1 30% and DLCO 30% of predicted value). The pres-
ence of supraclavicular lymph nodes, pleural fluid that was nega-
tive for malignancy on cytological examination and cardiac co-
morbidities including arrhythmia or a decreased ejection fraction
were no exclusion criteria. Patients with other invasive cancers
within the last five years were also allowed provided they were
in clinical complete remission at the time of enrollment.Study design and procedures
Chemotherapy was given in the referring hospital. It consisted
of 1 cycle of cisplatin or carboplatin–gemcitabine (cisplatin
75 mg/m2, carboplatin AUC 5, gemcitabine 1250 mg/m2), followed
by concurrent cisplatin–vinorelbine (cisplatin 40–50 mg/m2,
vinorelbine 15–20 mg/m2) or concurrent cisplatin–etoposide every
3 weeks (cisplatin 75–80 mg/m2 day 1 or carboplatin AUC 5
depending on the cardiovascular history or limited renal function,
etoposide 100 mg/m2 day 1–3) with radiotherapy. The regimen
depended on the referring hospital. Dose-reduction was applied
according to guidelines and in case of renal failure cisplatin was
substituted by carboplatin. Radiation treatment planning was per-
formed during the first cycle of chemotherapy and radiotherapy
was intended to start at the first day of the second cycle of
chemotherapy, according to Dutch guidelines. The study was
approved by the institutional review board and registered on clin-
icaltrials.gov (NCT01166204). Informed consent was obtained from
all patients prior to radiotherapy.Radiotherapy treatment planning
A PET-CT scan and a 4D-CT scan were performed before start of
radiotherapy (Biograph TruePoint 40, Siemens Healthineers, Ger-
many) and delineation was based on fused PET-CT images. The
total gross tumor volume (GTV) consisted of the primary tumor
(GTV-1; CT based volume based on the midventilation scan). Only
the initial PET-positive lymph nodal areas, based on the diagnostic
PET-CT before any treatment, and nodes proven to be malignant on
mediastinoscopy or EBUS were included in GTV-2. No elective
mediastinal irradiation was carried out. For the Clinical Target Vol-
ume (CTV-1 and CTV-2) a margin of 5 mm around the GTV was
used. The Planning Target Volume (PTV) was created by adding a
10 mm margin to CTV-1 and a 5 mm margin to CTV-2. For the cal-
culation of the mean lung dose (MLD), the volume of both lungs
minus GTV was considered. The external surface of the esophagus
was delineated from the cricoid to the gastro-esophageal junction.
The spinal cord was drawn at the inner margin of the bony spinal
canal.
An IMRT plan was calculated (XiO 4.3.4, CMS, Inc., USA) accord-
ing to the ICRU Report 83 using a Fast Fourier Transform
convolution-superposition algorithm taking into account inhomo-
geneity corrections. Patients were irradiated with Siemens Oncor
linear accelerators. All patients were treated with 6MV or 10MVphoton beams. Treatment verification was performed using EPID
measurements.Treatment description
For all patients enrolled, the prescribed dose was individually
escalated until the following dose-limiting normal tissue con-
straints were reached: MLD of 19.0 ± 1.0 Gy, spinal cord Dmax of
54.0 ± 0.5 Gy, plexus brachialis Dmax of 66 Gy, V35 of the esopha-
gus 65% or Dmax of 74 Gy, mean heart dose of 46 Gy and medi-
astinal structures (including the large blood vessels and the
bronchi up to the third generation) at a Dmax of 69 Gy. Since most
tumors were centrally located and/or had involved mediastinal
nodes the maximal allowed dose was 69 Gy to respect a dose inho-
mogeneity with a maximum of 107% to great vessels or main
bronchi of 74 Gy. The dose was delivered in an accelerated scheme:
1.5 Gy fractions twice daily up to 45 Gy with an interfraction inter-
val of at least 8 h, followed by once daily fractions of 2 Gy based on
the ESPATÜ phase III trial scheme [15]. The biological equivalent
dose for tumor in 2 Gy fractions was calculated using the linear
quadratic model (25–27) and corrected for overall treatment time
(EQD2,T).Endpoints
The primary endpoint was OS, secondary endpoints were loco-
regional relapses and toxicity. Patients were seen before start of
radiotherapy, weekly during treatment, 1 month after radiother-
apy and according to the standard protocol in the region, every
3–6 months for the first 2 years and yearly afterward. Toxicity
was scored according to Common Terminology Criteria for Adverse
Events v4.0 (CTCAE). Clinical tests (imaging) were used to deter-
mine local progression or distant failure. Local progression was
defined as at least a 20% increase in the sum of diameters of target
lesions. If progression was suspected a (PET-)CT was performed
and if necessary, a biopsy was considered. These patients were dis-
cussed at the MDT. Survival status was evaluated on July 27, 2018,
using the GBA system, a decentralized population registration sys-
tem containing information about all inhabitants of The
Netherlands.
As is standard procedure at Maastro Clinic, the toxicity of
patients was evaluated on a bi-yearly basis with all radiation
oncologists and physicists, in order to make sure that not more
than expected toxicity occurred.Statistical analysis
Based on the results of our previous study [6], we hypothesized
that IMRT would enable us to escalate the radiotherapy dose to 3D-
CRT that would lead to an increase in the median OS with
2.5 months, i.e. from 25 months to 27.5 months. A sample size of
185 patients was estimated to show with a power of 80% our
hypothesis. OS was defined as time from the first day of treatment
NSCLC until death using the Kaplan–Meier method (log-rank test
for comparison of survival). Median survival rates are expressed
with their 95% confidence intervals (CI). Crude incidences of pul-
monary complaints (cough and dyspnea) and esophageal dyspha-
gia were also calculated. SPSS23 was used for calculations.
Results
Patient characteristics
FromMay 4, 2009 to April 26, 2012, 185 patients were included.
Their characteristics, including previous malignancies, are depicted
in Table 1. Most patients were male and their mean age was almost
Table 1
Patient and tumor characteristics. Results are expressed as proportions or as the
mean ± standard deviation and the range, unless otherwise indicated.
Gender
Male: 113 (61.1%)
Female: 72 (38.9%)
Age (years)
63.9 ± 8.9 (44–86)
Body Mass Index (kg/m2)
24.6 ± 4.6 (16.3–35.0)
Smoking
Never 2.9%
Current 36.8%
Former 60.3%
Pack Years 34.3 ± 18.6 (0–90)
Weight loss last 6 months
>10%: 10.8%
<10%: 89.2%
FeV1 (% predicted value)
Mean: 79.5 ± 21.4% (30.1–122.0)
Median: 81.0%
50%: 17 patients (9.2%)
DLCO (% predicted value)
Mean: 69.2 ± 20.1% (31.5–120.0)
Median: 68.0%
40%: 9 patients (4.7%)
WHO performance status
0 67
(36.2%)
1 105
(56.8%)
2 11
(5.9%)
3 1
(0.2%)
4 1
(0.2%)
Other invasive cancer within the last 5 years
32 patients (17.3%)
Non-small cell lung cancer:11 patients
Small cell lung cancer: 1 patient
Head and neck cancer: 6 patients: floor of mouth
(1), tongue (2), parotic gland (1), supraglottic
(1), vallecular (1)
Breast cancer: 3 patients
Soft tissue sarcoma grade 1: 2 patients
Renal cell cancer: 1 patient
Prostate cancer: 1 patient
Rectal cancer: 1 patient
Bladder cancer: 1 patient
Melanoma skin cancer: 1 patient
Astrocytoma grade 3: 1 patient
Squamous cell carcinoma of the esophagus: 1
patient
Diffuse large cell B-cell lymphoma: 1 patient
Histology
Squamous 55
(29.7%)
Adenocarcinoma 49
(26.9%)
Large cell 26
(14.1%)
NSCLC-NOS 55
(29.7%)
Location of the primary tumor (number of patients/
percentage)
Right lower lobe 15 (8,5%)
Middle lobe 9 (4.6%)
Right upper lobe 70 (37.8%)
Left lower lobe 17 (9%)
Left upper lobe 69 (37.3%)
Unknown (‘‘Tx”) 5 (2.8%)
Table 1 (continued)
Lymph node involvement (number of patients/
percentage)
Station Right
side
Left
side
1 19
(10,3%)
9
(4.8%)
2 57
(30.9%)
12
(6.6%)
3 15
(8.1%)
3
(1.5%)
4 90
(48.5%)
53
(28.7%)
5 38
(20.6%)
6 23
(12.5%)
7 88
(47.8%)
8 8
(4.4%)
10 60
(32.4%)
46
(25.0%)
Gross tumor volume (GTV) (sum of primary tumor
and nodes) (ml)
Mean: 120.4 ± 132.0 ml (16.8–708.5)
Median: 72.6 ml
Percentiles:
25: 43.95 ml
50: 72.57 ml
75: 146.82 ml
D. De Ruysscher et al. / Radiotherapy and Oncology 135 (2019) 141–146 14364 years. Ninety-seven percent was current or former smokers and
11% had weight loss over 10%. Nearly all patients had a WHO-PS 0–
1, although 11 had PS 2 and 2 PS 3 or 4, which are clearly protocol
violations. The mean volume of the tumor and the nodes together
(GTV) was 120 ml (range 17–709).Radiotherapy
The mean tumor dose was 66.0 ± 12.8 Gy, ranging from 36 Gy to
73 Gy, delivered in a mean of 39.7 fractions in an overall treatment
time of 38.2 days (Table 2). The dose distribution is depicted in
Table 2. The mean MLD was 17.3 Gy and the V20 27.4%. The mean
esophageal dose was 29.0 Gy. The mediastinal structures were
dose-limiting in 67% of the patients.
As expected because of the study design, there was a significant
inverse correlation between the GTV and the tumor dose, with big-
ger GTVs receiving less dose (p = 0.04).Overall survival
Themedian OSwas 19.8 months (95% CI 17.3–22.3) with a 5-year
OS of 24.3% (Fig. 1). The 3 months, 1, 2 and 3-year OS were 93.5%,
68.6%, 43.8% and 34.1%, respectively. The 6-year OS was 20.5%.
In a univariate analysis for OS, only the WHO-PS (better PS 0 vs.
1 was associated with a better OS; p = 0.006) was highly signifi-
cantly related to the OS, whereas the GTV (bigger tumors have a
worse OS, p = 0.048) (Fig. 2) and the total tumor dose (higher doses
associated with a better OS; p = 0.045) were only borderline statis-
tically significant. In a multivariate Cox regression analysis for OS,
only the WHO-PS (p = 0.002) remained significantly related to the
OS (GTV: p = 0.25; total radiation dose: p = 0.70).Loco-regional failures
Loco-regional failures as first site of recurrence occurred in
59/185 patients (31.8 %). Isolated nodal failures (INF) were
observed in 3/185 patients (1.6%) (Fig. 3A–C).
Table 2
Radiotherapy. Results are expressed as proportions or as the mean ± standard
deviation and the range.
Total Tumor Dose (Gy)
Mean: 65.5 ± 5.6 (36.0–73.0)
Median: 69 Gy
Percentiles:
25: 63 Gy
50: 69 Gy
75: 69 Gy
Number of fractions
39.7 ± 3.4 (24–44)
Overall treatment time (days)
38.2 ± 26.8 (16–93)
Mean Lung Dose (MLD) Gy
17.3 ± 3.0 (4.9–21,2)
V20 (%)
27.4 ± 5.6 (20.7–37.0)
Mean Esophageal Dose (Gy)
29.0 ± 9.3 (6.3–54.1)
Fig. 1. Overall survival.
Fig. 2. Relation between overall survival and tumor volume. Median overall
survival as a function of the total tumor volume. Circles depict patients, the full line
is the logarithmic curve estimation (R2 = 0.040). Larger tumors have a lower median
overall survival than smaller and the smallest tumors have the best survival.
Fig. 3. (A) Local progression. Actuarial calculation of loco-regional tumor progres-
sion. (B) Relation between total tumor volume, tumor dose and local progression.
Total tumor volume (primary tumor and involved lymph nodes) per percentile as a
function of the cumulative incidence of local progression. The differences between
the percentiles tumor volume are statistically significant (p < 0.001; log-rank test).
The mean tumor dose and standard deviation per percentile tumor volume is
depicted on the right side. (C) Relation between tumor dose and local progression.
Local tumor progression as a function of the radiotherapy dose below (full line) or
above (dotted line) the median (69 Gy). The difference is not statistically different
(p = 0.57, log-rank test).
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Toxicity is depicted in Table 3.Dyspnea
Only 55% of the patients had no dyspnea before treatment.
Approximately 56% of the patients had dyspnea grade 1 post treat-
ment (37% before therapy), 2.7% grade 2 and 3.2% grade 3.Dysphagia
No patient had dysphagia before treatment. About 44% of the
patients developed grade 2 dysphagia and 22% grade 3. All dyspha-
gia reversed to grade 0 within 3 months after therapy.Discussion
There is an obvious need to improve the prognosis of patients
with stage III NSCLC [1]. As the improved prognosis of patients
treated with concurrent chemotherapy and radiotherapy over the
sequential approach is thought to be due to improved local tumor
control, many groups, including ours, have intensified the local
treatment to try to improve the OS [6–12,16]. One possibility to
increase the dose intensity is to prescribe the dose in an isotoxic
way, which leads to the highest achievable dose with a constant
level of side effects and at the same time to decrease the overall
treatment time. Our previous studies were done with 3D-CRT
and suggested that for sequential chemotherapy and radiotherapy
and for radiotherapy alone, individualized, accelerated isotoxic
radiotherapy is beneficial [13]. For 3D-CRT individualized, acceler-
ated isotoxic radiotherapy concurrent with chemotherapy the
long-term benefit of this strategy was uncertain [6].
As with IMRT we assumed that more patients should be able to
receive a higher dose than with 3D-CRT [14], we studied this strat-
egy prospectively in concurrent chemotherapy and radiotherapy
and report here on the long-term data with a minimum follow-
up of 5 years.
In the present study in stage III NSCLC patients, with isotoxic,
accelerated radiotherapy given concurrently with standard
chemotherapy, we could in the average patient only deliver about
66 Gy in 5 weeks (45 Gy/30 fractions BID of 1.5 Gy, followed by
about 20 Gy/10 fractions QD of 2 Gy).
The toxicity was comparable to large series giving 60–66 Gy in
2 Gy QD fractions in 6–6.6 weeks, with only about 3% of dyspnea
grade 3 and 22% transient grade 3 dysphagia. The strategy followed
in this study is therefore safe.
The rate of local progression was also comparable to other ser-
ies [2,17].
However, the OS (median 20 months and 5-year 25%) is cer-
tainly not superior compared with recent series who deliveredTable 3
Toxicity.
Dyspnea
Grade Baseline Maximal score
0 102 (55.1%) 71 (38.4%)
1 68 (36.8%) 103 (55.7%)
2 15 (8.1%) 5 (2.7%)
3 0 6 (3.2%)
Dysphagia
Grade Maximal score
0 23 (12.4%)
1 41 (22.2%)
2 81 (43.8%)
3 40 (21.6%)the standard dose and fractionation schedule of 60–66 Gy in 30–
33 QD fractions [2,15,17]. It may even be argued that in some of
these studies the median and the 5-year OS results were better
than in the current trial, but this may be due to our less stringent
patient selection (10% of our patients had over 10% of weight loss
over the last 6 months, the mean tumor volume was 120 ml, 13%
had a WHO performance status of 2 or more, 17% had an invasive
malignancy in the 5 years preceding enrollment and no restrictions
for cardiac illness were included) and because in the present study
the minimum follow-up was 5 years, which is longer than in most
other trials. The bigger GTV in the present series compared to our
previous study (120 ml vs. 76 ml, respectively) [6] may also
explain the worse OS than expected. In order to estimate the
impact of patients with negative prognostic factors in the present
study, in an unplanned exploratory analysis, we omitted patients
who would not be eligible for RTOG0617 [2], ESPATUE [15] or PRO-
CLAIM [17]. Because we had no data on cardiac illness, we could
not take this factor into account, in contrast to phase III studies
that excluded patients with important cardiac co-morbidities,
including uncontrolled cardiac arrhythmia [17] or a decreased
ejection fraction [2]. Out of 185 patients, 59 (31.9%) were thus
excluded. The median survival in this ‘‘good prognostic” group
was 22.8 months (95% CI 15.7–30.0), with a 1-, 2-, 3-, 4- and 5-
year OS of 71.8%, 49,1%, 39,1%, 35.5% and 29.1%, respectively. The
median OS in PROCLAIM was 25 months with a 3-year OS of 37%
[17]. In RTOG0617, the median OS was 28.7 months and
20.3 months in the 60 Gy and 74 Gy arm, respectively and a 1-
and 2-year OS of 76.2%, 71.1% and 57.6% and 44.6% in the 60 Gy
and 74 Gy arm, respectively [2]. The ESPATUE trial included only
operable patients [15]. For the whole group, the 5-year OS was 33%.
Because our minimum follow-up exceeds 5 years in contrast to
some recent phase III studies [2,17], our 5-year data will not fur-
ther decrease because of actuarial calculations. We therefore
believe that the OS of our patients with similar prognostic factors
as in many other series is in the same range as expected, but there
is no signal that our treatment schedule would be superior.
There is also no hint that this schedule would be harmful for
patients, neither for OS, nor for local failure, nor for toxicity, which
is in line with the results of the ESPATUE trial [15].
In the absence of a randomized comparison, it is not possible to
draw firm conclusions, but we believe that our results do not sup-
port to use isotoxic, accelerated radiotherapy given concurrently
with standard chemotherapy as a way to improve the prognosis.
The reasons for failure of isotoxic accelerated dose delivery with
concurrent chemotherapy may be similar to that observed in phase
III trials in head and neck cancer [18–21]. It seems that concurrent
chemotherapy suppresses accelerated repopulation of tumor
clonogens sufficiently, neutralizing the effect of treatment acceler-
ation. In contrast to head and neck cancer, the schedule used in our
study did not increase the toxicity. This may be due to a quite flat
initial dose–response between the lung dose and dyspnea, the
small time factor for radiation pneumonitis and to the observation
that for acute dysphagia other parameters than radiation dose and
volume are important, such as the level of neutropenia [22–24].
Radiation dose escalation by dose-redistribution within the
tumor may theoretically lead to improved local tumor control
without increasing side effects [3–5]. However, due to the medi-
astinal dose constraints, the dose escalation in the present series
was moderate at best and possibly too low to lead to improved
OS or local progression. The results of the completed or ongoing
randomized studies testing higher dose escalation are eagerly
awaited.
Nevertheless, the improvement in OS seen in the PACIFIC study
by adding durvalumab after concurrent chemo-radiotherapy is
pointing to the fact that immune therapy in combination with
standard therapy is probably the most promising strategy for
146 Long-term results INDARimprovement of OS in stage III NSCLC [25]. Optimizing the combi-
nation of radiotherapy with immune therapy, as for instance is
being tested in the NICOLAS trial (NCT02434081), is an example
of this.
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